Motilium, containing domperidone, primarily works by blocking dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the brain and the gastrointestinal tract. This action reduces nausea and vomiting.
Simultaneously, domperidone stimulates the release of acetylcholine in the gastrointestinal tract. This stimulates gut motility, accelerating gastric emptying and speeding the movement of food through the intestines. This helps relieve symptoms like bloating and indigestion.
Importantly, domperidone doesn’t cross the blood-brain barrier significantly, minimizing potential neurological side effects compared to other antiemetics. This difference in its action is key to understanding its unique properties.
| Dopamine D2 receptor blockade | Chemoreceptor trigger zone (CTZ) | Reduces nausea and vomiting |
| Dopamine D2 receptor blockade | Gastrointestinal tract | Reduces nausea and vomiting |
| Acetylcholine release stimulation | Gastrointestinal tract | Increases gut motility |
Therefore, Motilium’s dual action on both the brain and the gut contributes to its efficacy in treating various gastrointestinal disorders. This targeted approach differentiates it from other medications.
